ArticleBMJ open2025
Analysis of risk factors associated with metabolic-associated fatty liver disease from Suzhong Region, China: a cross-sectional study.
Article in BMJ open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesMetabolic-associated fatty liver disease (MAFLD) is becoming increasingly prevalent worldwide, however, early diagnosis and intervention remain underachieved. This study aims to guide the prevention and diagnosis of MAFLD by analysing its risk factors within the adult population from Suzhong Region, China.
designThis was a cross-sectional study.
settingThe study was conducted at the Health Management Department of Northern Jiangsu People's Hospital.
participantsA total of 49 776 asymptomatic Chinese participants (54.24% men) were enrolled. OUTCOME MEASURES: Hepatic ultrasonography was performed to diagnose MAFLD based on the latest diagnostic criteria. The relevant blood routine and biochemical indicators were collected.
resultsAmong 49 776 participants, the prevalence of MAFLD was 29.89% (14 877/49 776). The results of restricted cubic spline (RCS) analysis showed a nonlinear relationship between age and MAFLD prevalence. As age increased, the overall trend of age in relation to MAFLD prevalence was initially increasing and then decreasing in the total study population and in males. In contrast, the overall trend of age in relation to MAFLD prevalence in females was initially increasing and then levelling off. The study found that age, body mass index (BMI), red blood cell (RBC) count, white blood cell (WBC) count, fasting blood glucose, albumin, total bilirubin, alanine aminotransferase (ALT), uric acid, triglycerides (TG) and low-density lipoprotein cholesterol were risk factors for MAFLD in adults, while aspartate aminotransferase, direct bilirubin, blood urea nitrogen, serum creatinine and high-density lipoprotein cholesterol were protective factors (p<0.05). Among these, BMI, ALT, TG, triglyceride-glucose index (TyG), triglyceride glucose-body mass index (TyG-BMI) and Atherogenic Index of Plasma (AIP) had excellent predictive value for the occurrence of MAFLD in adults (area under the curve was 0.834, 0.803, 0.809, 0.822, 0.880 and 0.824, respectively). The clinical applicability of important feature variables was assessed using decision curve analysis curves and confusion matrix, and the results showed that TyG-BMI had the highest clinical diagnostic and decision-making benefits.
conclusionsThe occurrence of MAFLD has a nonlinear relationship with age and the trend of this relationship varies significantly between males and females. BMI, ALT, TG, TyG, TyG-BMI and AIP are helpful factors in the diagnosis of MAFLD, especially TyG-BMI. TRIAL REGISTRATION NUMBER: Clinical trials from the Northern Jiangsu People's Hospital (SBLC23002).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.